Drugs / BI 44847
last change Dec 2008 re-read 2 minutes ago

BI 44847

Developed for
type 2 diabetes mellitus
Investigated by
Boehringer Ingelheim

Trials 5 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02211950 Oct → Dec 2008 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02211924 Aug → Sep 2007 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT00558909 Jun → Nov 2007 type 2 diabetes mellitus Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02211963 Feb → Jun 2007 type 2 diabetes mellitus Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02209844 Aug 2006 → Jan 2007 Boehringer Ingelheim Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02211937 Comparator Jan → Mar 2007 Boehringer Ingelheim Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as BI 44847 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02211963
5

NCT02209844

NCT02211924

NCT02211950

NCT00558909

NCT02211937

Route Oral “following oral administration” NCT00558909